Skip to main content

Telix Pharmaceuticals Limited (TLX) Stock Forecast

Data as of Aug 7, 2026

Healthcare · Current price $10.63 (+1.97%)

Consensus Target
$19.00
Upside
+81.5%
Analysts
5
Rating
Buy(2.00)

Price Target Range

Low $17.00Consensus $19.00High $20.00
▲ Current $10.63

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

TLX vs Sector & Market

MetricTLXHealthcare AvgLarge Cap Avg
Analyst Rating2.002.252.42
Analyst Count5818
Target Upside+81.5%+16316.1%+17.2%
P/E Ratio-459.893.8435.26

Revenue Estimates

PeriodLowAvgHigh#
2028-06-30$564M$567M$571M1
2028-09-30$604M$608M$612M1
2028-12-31$611M$614M$618M1
2029-03-31$611M$614M$618M1
2029-06-30$763M$768M$772M1
2029-09-30$850M$855M$860M1
2029-12-31$1.06B$1.07B$1.08B1
2030-03-31$1.06B$1.07B$1.08B1

EPS Estimates

PeriodLowAvgHigh#
2028-06-30$0.19$0.19$0.201
2028-09-30$0.05$0.05$0.051
2028-12-31$0.06$0.07$0.071
2029-03-31$0.06$0.07$0.071
2029-06-30$0.13$0.13$0.131
2029-09-30$0.22$0.22$0.221
2029-12-31$0.41$0.41$0.411
2030-03-31$0.41$0.41$0.411

Frequently Asked Questions

What is the analyst consensus for TLX?

The consensus among 5 analysts covering Telix Pharmaceuticals Limited (TLX) is Buy with an average price target of $19.00.

What is the highest price target for TLX?

The highest analyst price target for TLX is $20.00.

What is the lowest price target for TLX?

The lowest analyst price target for TLX is $17.00.

How many analysts cover TLX?

5 analysts have issued ratings for Telix Pharmaceuticals Limited in the past 12 months.

Is TLX a buy or sell right now?

Based on 5 analyst ratings, TLX has a consensus rating of Buy (2.00/5) with a +81.5% upside to the consensus target of $19.00.

What are the earnings estimates for TLX?

Analysts estimate TLX will report EPS of $0.19 for the period ending 2028-06-30, with revenue estimated at $567M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.